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Background: Nine randomized controlled clinical trials, including approximately 26,000 children aged
6 months to 17 years, have evaluated the efﬁcacy of live attenuated inﬂuenza vaccine (LAIV) against
culture-conﬁrmed inﬂuenza illness compared with placebo or trivalent inactivated inﬂuenza vaccine
(TIV). The objective of the current analysis was to integrate available LAIV efﬁcacy data in children aged
2–17 years, the group for whom LAIV is approved for use.
Methods: A meta-analysis was conducted using all available randomized controlled trials and a ﬁxed-
effects model. Cases caused by drifted inﬂuenza B were analyzed as originally classiﬁed and with all
antigenic variants classiﬁed as dissimilar.
Results: Five placebo-controlled trials (4 were 2-season trials) and 3 single-season TIV-controlled trials
were analyzed. Comparedwith placebo, year 1 efﬁcacy of 2 doses of LAIVwas 83% (95% CI: 78, 87) against
antigenically similar strains; efﬁcacy was 87% (95% CI: 78, 93), 86% (95% CI: 79, 91), and 76% (95% CI: 63,
84) forA/H1N1,A/H3N2, andB, respectively. ClassifyingBvariants as dissimilar, efﬁcacy against all similar
strains was 87% (95% CI: 83, 91) and 93% (95% CI: 83, 97) against similar B strains. Year 2 efﬁcacy was
87% (95% CI: 82, 91) against similar strains. Comparedwith TIV, LAIV recipients experienced 44% (95% CI:
28, 56) and 48% (95% CI: 38, 57) fewer cases of inﬂuenza illness caused by similar strains and all strains,
respectively. LAIV efﬁcacy estimates for children from Europe, the United States, and Middle East were
robust and were similar to or higher than those for the overall population.
Conclusions: In children aged 2–17 years, LAIV demonstrated high efﬁcacy after 2 doses in year 1 and
revaccination in year 2, and greater efﬁcacy compared with TIV. This meta-analysis provides precise
estimates of LAIV efﬁcacy among the approved pediatric age group.
© 2011 Elsevier Ltd. Open access under CC BY-NC-ND license.. Introduction
Inﬂuenza affects an estimated 1 billion people annually world-
ide [1], with up to 5 million cases of severe illness and 500,000
eaths attributable to infection with inﬂuenza each year [2]. For
pidemiologic and immunologic reasons, children are among the
ost susceptible to inﬂuenza infection and are primarily respon-
ible for transmitting the illness to others [3–8]. Annual inﬂuenza
Abbreviations: AOM, acute otitis media; LAIV, live attenuated inﬂuenza vaccine;
R, relative risk; TIV, trivalent inactivated inﬂuenza vaccine.
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vaccination is the principal measure for preventing inﬂuenza dis-
ease [2]; however, in many countries, inﬂuenza vaccination is not
currently recommended for the vast majority of children.
A live attenuated inﬂuenza vaccine (LAIV, MedImmune,
Gaithersburg, MD, USA) has been approved for use in many coun-
tries in eligible children and adolescents 2 years of age and older.
The vaccine was originally derived at the University of Michigan
by cold adaptation of an inﬂuenza type A strain (A/Ann Arbor/6/60
H2N2) and a type B strain (B/Ann Arbor/1/66) through serial pas-
sage at sequentially lower temperatures. During this process, the
Ann Arbor strains acquired multiple mutations in genes encod-
ing internal nonglycosylated proteins, resulting in master donor
viruses with a cold-adapted, temperature-sensitive, and attenu-
ated phenotype. These vaccine strains are updated annually to
produce a trivalent vaccine with A/H1N1, A/H3N2, and type B
inﬂuenza strainswith hemagglutinin (HA) andneuraminidase (NA)
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roteins that match those of the strains selected for the spe-
iﬁc annual formulation. The vaccine is administered as a nasal
pray using the Accuspray device (Becton Dickinson, Franklin Lakes,
J, USA).
Nine randomized, controlled clinical trials have evaluated the
fﬁcacy of LAIV against culture-conﬁrmed inﬂuenza illness com-
ared with placebo or trivalent inactivated inﬂuenza vaccine (TIV)
9–18]. A previous meta-analysis of these trials by Rhorer et al. [19]
valuated the efﬁcacy of LAIV in children in all subjects enrolled,
any of whom were 6–23 months of age. Additionally, the meta-
nalysis by Rhorer et al. relied on summary statistics from each
rial instead of subject-level data and thus the effects of subject
haracteristics such as gender and geographic region could not be
xplored. Lastly, results of TIV-controlled studies by inﬂuenza type
nd subtype were not explored by Rhorer et al. The objective of this
nalysis was to evaluate the efﬁcacy of LAIV in children 2–17 years
f age overall and by type/subtype, including the effects of various
ubject characteristics, using data from all available randomized
ontrolled trials. This is the ﬁrst meta-analysis conducted for chil-
ren 2–17 years of age, the age group for whom LAIV is approved
or use.
.  Methods
.1. Trials used in meta-analysis
Of  the 9 randomized, controlled trials evaluating the efﬁcacy of
AIV against culture-conﬁrmed inﬂuenza in children, one was  con-
ucted exclusively in children younger than 24 months and was
xcluded from analysis. Of the remaining 8 trials that enrolled chil-
ren 2–17 years of age, 5 compared LAIV with placebo, of which 4
valuated children vaccinated for 2 consecutive inﬂuenza seasons
Table 1) [9,11–15]. Placebo-controlled trials enrolled children in
ear 1 who had not been previously vaccinated against inﬂuenza.
hree trials compared LAIV with TIV (Table 1) [16–18] over a single
nﬂuenza season. These trials enrolled children regardless of previ-
us inﬂuenza vaccination. In the Ashkenazi et al. study, all subjects
eceived 2 doses of vaccine, while in the Fleming et al. study, all
ubjects received a single dose of vaccine [16,18]. In the study by
elshe et al., previously unvaccinated children received 2 doses of
accine, while previously vaccinated children were administered a
ingle dose of vaccine [17].
.2.  Planned analysis
All  previous analyses of the studies in question have shown that
fﬁcacy results were similar for the per-protocol and intent-to-
reat populations. Accordingly, the current analysis was  limited to
he per-protocol population of children ≥24 months of age at vac-
ination. Efﬁcacy in year 1 was measured for children ≥24 months
f age at enrollment; efﬁcacy in year 2 was measured for children
24 months of age at year 2 vaccination. The prespeciﬁed end-
oints of interest were efﬁcacy relative to placebo and TIV against
ulture-conﬁrmed inﬂuenza illness caused by antigenically similar
trains and all strains regardless of antigenic match. Dosing regi-
ens inconsistent with the recommended use of LAIV (e.g. low titer
ormulations or use of a single dose in previously unvaccinated chil-
ren) were not examined. Predeﬁned subgroup analyses included
fﬁcacy by inﬂuenza type/subtype (A/H3N2, AH1N1, B), by gender,
nd by region.
Classiﬁcation of drifted, antigenic variant inﬂuenza B virusesaried across trials, with some classifying them as antigenically
imilar and others classifying them as antigenically dissimilar [20].
n the current analysis, illnesses caused by drifted inﬂuenza B
iruses were analyzed as originally classiﬁed by the trials and 30 (2012) 886– 892 887
secondarily  by classifying all antigenic variants of B viruses as dis-
similar.
2.3. Vaccines and placebo
In  all trials, LAIV consisted of 106.5–7.5 median tissue cul-
ture infectious doses (TCID50) or ﬂuorescent focus units of each
of the 3 inﬂuenza strains (A/H1N1, A/H3N2, and B). Placebo
did not differ in appearance, delivery, or taste. In one study, 2
different placebo formulations (saline and excipient) were investi-
gated; for this meta-analysis, as in the original study, data from
these 2 groups were combined [12]. TIV-controlled trials used
commercially-available TIV approved for use in the correspond-
ing region; children 6 months to younger than 36 months received
0.25 mL  per dose (7.5 g of each hemagglutinin) while children 36
months and older received 0.5 mL  per dose (15 g of each hemag-
glutinin). For the trials in which children received 2 doses, the time
between doses was  approximately 1 month, with the exception of
one study in which the interval was 6–10 weeks [9,11].
2.4.  Inﬂuenza case deﬁnition
Culture-conﬁrmed symptomatic inﬂuenza illness was deﬁned
by a positive viral culture of a wild-type inﬂuenza virus. Nasal
swab cultures were collected if a child had (1) ≥1 of the follow-
ing: acute otitis media (suspected or diagnosed), fever, pneumonia,
pulmonary congestion, shortness of breath, or wheezing or (2) ≥2
of the following symptoms concurrently: chills, cough, decreased
activity, headache, irritability, muscle aches, pharyngitis, rhinor-
rhea, or vomiting. Criteria for obtaining a culture were generally
consistent across trials, with the exception of slight variations in
the deﬁnition of fever (minimum of ≥37.5 ◦C axillary, ≥38 ◦C oral,
rectal, or tympanic), the start of surveillance after receiving the
ﬁrst dose (from 11 to 15 days or a speciﬁed date), and the rec-
ommended time between the onset of symptoms and collection of
culture (from 24 h to 4 days) [19]. In all trials, central laboratories
evaluated nasal swabs for the presence of inﬂuenza virus and sub-
types, and serotypes were identiﬁed through antigenic methods.
2.5.  Statistical analysis
Subject-level data were extracted for eligible children from the
clinical trial databases for each relevant study (Table 1). The data
were analyzed using the SAS System for Windows version 8.2 (Cary,
NC, USA). The meta-analysis was  conducted on the per-protocol
population using the ﬁxed-effects model [21]. A log binomial model
was  used to calculate LAIV relative risk adjusting for study varia-
tion. LAIV efﬁcacy relative to placebo and TIV was  calculated as 1
minus the adjusted relative risk (RR) of culture-conﬁrmed inﬂuenza
in LAIV recipients relative to placebo or TIV recipients, respectively.
The 95% CI of LAIV efﬁcacy was  constructed from the 95% CI of the
adjusted RR. The Cochran Q statistic was used to assess the hetero-
geneity of the effects across trials [22]. Studies with no inﬂuenza
cases for a particular subtype were excluded from the correspond-
ing analysis.
3.  Results
The 8 trials included 4288 children 24–71 months of age in
placebo-controlled trials and 7986 children 24 months to 17 years
of age in TIV-controlled trials (Table 1). Demographics were simi-
lar among LAIV recipients and TIV and placebo controls. Children in
TIV-controlled studies were older than those in placebo-controlled
trials due to the inclusion of the TIV-controlled study in children
6–17 years of age.
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Table 1
Trials  comparing LAIV with placebo and TIV in children 2–17 years of age.
Study, period Population, geography Age range
(mo)
Treatment group
(doses,  n)
N Vaccine strains Predominant circulating strain(s)
Trials comparing LAIV with placebo
Belshe (1998) [11]
Year  1: Aug 1996–Apr 1997
United  States 24–71 LAIV (2)
Placebo (2)
717
342
A/Texas/36/91-like (H1N1), A/Wuhan/359/95-like
(H3N2), B/Harbin/7/94-like
A/Wuhan/359/95-like (H3N2),
B/Harbin/7/94-like
Belshe (2000) [9]
Year  2: Sep 1997–May 1998
United  States 24–83 LAIV (1)
Placebo (1)
748
362
A/Shenzhen/227/95-like (H1N1), A/Wuhan/359/95
(Nanchang-like) (H3N2), B/Harbin/7/94-like
A/Sydney/5/97 (H3N2) (antigenic variant)
Tam  (2007) [14]
Year  1: Sep 2000–Oct 2001
Asia  24–35 LAIV (2)
Placebo (2)
782
534
A/New Caledonia/20/99 (H1N1), A/Sydney/05/97
(H3N2), B/Yamanashi/166/98 (Beijing-like)
A/New Caledonia/20/99-like (H1N1),
A/Panama/2007/99-like (H3N2),
B/Sichuan/379/99-like (antigenic variant),
B/Hong Kong/330/01-like (opposite
lineage)
Tam (2007) [14]
Year  2: Nov 2001–Oct 2002
Asia  24–47 LAIV (1)
Placebo (1)
771
494
A/New Caledonia/20/99 (H1N1),
A/Panama/2007/99 (H3N2), B/Yamanashi/166/98
A/New Caledonia/20/99-like (H1N1),
A/Panama/2007/99-like (H3N2),
B/Sichuan/379/99-like (antigenic variant),
B/Hong Kong/1351/02-like (opposite
lineage)
Vesikari (2006) [15]
Year  1: Oct 2000–May 2001
Children  attending day care
Europe, Israel
24–35 LAIV (2)
Placebo (2)
490
356
A/New Caledonia/20/99 (H1N1), A/Sydney/05/97
(H3N2), B/Yamanashi/166/98 (Beijing-like)
A/New Caledonia/20/99-like (H1N1),
B/Sichuan/379/99-like (antigenic variant)
Vesikari  (2006) [15]
Year  2: Dec 2001–May 2002
Children  attending day care
Europe, Israel
24–47 LAIV (1)
Placebo (1)
570
403
A/New Caledonia/20/99 (H1N1),
A/Panama/2007/99 (H3N2), B/Victoria/504/2000
A/New Caledonia/20/99-like (H1N1),
A/Panama/2007/99-like (H3N2),
B/Victoria/504/00-like, B/Hong
Kong/1351/02-like (opposite lineage)
Bracco Neto (2009) [12]
Year  1: Apr 2001–Nov 2001
South  Africa, South America 24–35 LAIV (2)
Placebo (2)
344
332
A/New Caledonia/20/99 (H1N1),
A/Panama/2007/99 (H3N2), B/Yamanashi/166/98
A/Panama/2007/99-like (H3N2),
B/Yamanashi/166/98-like
Bracco Neto (2009) [12]
Year  2: Mar  2002–Nov 2002
South  Africa, South America 24–47 LAIV (1)
Placebo (1)
265
276
A/New Caledonia/20/99 (H1N1),
A/Panama/2007/99 (H3N2), B/Victoria/504/2000
A/New Caledonia/20/99-like (H1N1),
A/Panama/2007/99-like (H3N2), B/Hong
Kong/1351/02-like (opposite lineage)
Forrest (2008) [13]
Feb  2002–Nov 2002
Asia  24–35 LAIV (2)
Placebo (2)
209
182
A/New Caledonia/20/99 (H1N1),
A/Panama/2007/99 (H3N2), B/Victoria 504/2000
A/Panama/2007/99-like (H3N2), B/Hong
Kong/330/01-like (opposite-lineage),
B/Hong  Kong/1351/02-like
(opposite-lineage)
Trials  comparing LAIV with TIV
Ashkenazi (2006) [16]
Oct  2002–June 2003
Children with 2 or more RTIs in
the past 12 months
Europe,  Israel
24–71 LAIV (2)
TIV  (2)
790
819
A/New Caledonia/20/99 (H1N1),
A/Panama/2007/99 (H3N2), B/Hong Kong/330/01
A/New Caledonia/20/99-like (H1N1),
A/Panama/2007/99-like (H3N2),
A/Fujian/411/2002-like (H3N2) (antigenic
variant), B/Hong Kong/1351/02-like
Fleming (2006) [18]
Oct  2002–May 2003
Children with a diagnosis of
asthma
Europe, Israel
6–17 years LAIV (1)
TIV  (1)
1109
1102
A/New Caledonia/20/99 (H1N1),
A/Panama/2007/99 (H3N2), B/Hong Kong/330/01
A/New Caledonia/20/99-like (H1N1),
A/Panama/2007/99-like (H3N2), B/Hong
Kong/1351/02-like
Belshe  (2007) [17]
Oct  2004–Aug 2005
Europe, Middle East, Asia,
United  States
24–59 LAIV (1/2)a
TIV (1/2)a
2083
2083
LAIV: A/New Caledonia/20/99 (H1N1),
A/Wyoming/3/2003 (H3N2), B/Jilin/20/2003
[B/Shanghai/361/2002-like]
TIV: A/New Caledonia/20/99 (H1N1),
A/Wyoming/3/2003 (H3N2), B/Jiangsu/10/2003
[B/Shanghai/361/2002-like]
A/New Caledonia/20/99-like (H1N1),
A/California/7/2004-like (H3N2),
B/Shanghai/361/2002-like,
B/Florida/7/2004-like (antigenic variant),
B/Hong Kong/330/01-like (opposite
lineage)
LAIV, live attenuated inﬂuenza vaccine; RTI, respiratory tract infection; TIV, trivalent inactivated inﬂuenza vaccine.
a Depending on previous inﬂuenza vaccinations; 2 doses were administered to those previously unvaccinated, 1 dose was administered to those previously vaccinated.
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Fig. 1. LAIV efﬁcacy versus placebo (year 1; 2 doses) for antigenically similar strains
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64) and overall relative efﬁcacy against all similar strains increased
to 50% (95% CI: 33, 62). For strains regardless of antigenic match,
LAIV recipients experienced 97% (95% CI: 78, 100) fewer illnessesy type/subtype and study. LAIV, live attenuated inﬂuenza vaccine. Symbol sizes are
elative to the study population sizes. See Table 1 for details of each study.
.1. Efﬁcacy of LAIV compared with placebo
For the per-protocol population receiving 2 doses of LAIV com-
ared with placebo after year 1, the estimated vaccine efﬁcacy
as 83% (95% CI: 78, 87; Table 2 and Fig. 1) against culture-
onﬁrmed inﬂuenza for antigenically similar strains (3% of LAIV
ersus 16% of placebo recipients developed inﬂuenza). By individ-
al type/subtype, efﬁcacy estimates were 87% (95% CI: 78, 93) for
/H1N1, 86% (95% CI: 79, 91) for A/H3N2, and 76% (95% CI: 63, 84)
or B. With antigenically drifted B strains classiﬁed as dissimilar,
fﬁcacy against similar B strains increased to 93% (95% CI: 83, 97)
nd overall efﬁcacy against all similar strains increased to 87% (95%
I: 83, 91). Vaccine efﬁcacy was 79% (95% CI: 73, 83) for all strains
egardless of antigenic match to the vaccine (4% of LAIV versus 18%
f placebo recipients developed inﬂuenza).
After revaccination in year 2, the estimated vaccine efﬁcacy
ompared with placebo was 87% (95% CI: 82, 91; Table 3 and Fig. 2)
gainst culture-conﬁrmed inﬂuenza caused by antigenically sim-
lar strains (1% of LAIV and 12% of placebo recipients developed
nﬂuenza). As in year 1, efﬁcacy was high against A/H1N1, A/H3N2,
nd B. Vaccine efﬁcacy was 78% (95% CI: 72, 82) for all strains
egardless of antigenic match (4% of LAIV and 18% of placebo recip-
ents developed inﬂuenza).
.2.  Relative efﬁcacy of LAIV compared with TIV
Compared with TIV, LAIV recipients overall experienced 44%
95% CI: 28, 56) and 48% (95% CI: 38, 57) fewer cases of inﬂuenza
llness caused by similar strains and all strains regardless of match,
espectively (Table 3 and Fig. 3). For similar strains by individual
ype/subtype, LAIV recipients experienced 97% (95% CI: 77, 100)
ewer illnesses caused by A/H1N1 and 41% (95% CI: 21, 56) fewerFig. 2. Live attenuated inﬂuenza vaccine efﬁcacy versus placebo (year 2; 1 revac-
cination  dose) for antigenically similar strains by type/subtype and study. Symbol
sizes  are relative to the study population sizes. See Table 1 for details of each study.
illnesses caused by B strains; no difference was seen for antigeni-
cally similar A/H3N2 strains (relative efﬁcacy, −31% [95% CI: −145,
30]). With antigenically drifted B strains classiﬁed as dissimilar, rel-
ative efﬁcacy against similar B strains increased to 49% (95% CI: 27,Fig. 3. LAIV efﬁcacy versus TIV (year 1; 1 and 2 doses) for all strains regardless
of  antigenic similarity by type/subtype and study. LAIV, live attenuated inﬂuenza
vaccine;  TIV, trivalent inactivated inﬂuenza vaccine. Symbol sizes are relative to the
study population sizes. See Table 1 for details of each study.
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Table 2
Efﬁcacy of LAIV versus placebo in years 1 and 2.
Inﬂuenza strain LAIV n/N (%) Placebo n/N (%) Vaccine efﬁcacy (95% CI) Heterogeneity (Q)
Following year 1 vaccination, antigenically similar strains
A/H1N1 14/1272 (1.1) 78/890 (8.8) 87 (78, 93) 0.1495
A/H3N2 26/2542 (1.0) 135/1746 (7.7) 86 (79, 91) 0.0025
B  (original classiﬁcation) 30/2333 (1.3) 82/1564 (5.2) 76 (63, 84) 0.0001
B  (variants as dissimilar) 6/1061 (0.6) 52/674 (7.7) 93 (83, 97) 0.8557
Any  strain (original classiﬁcation) 70/2542 (2.8) 281/1746 (16.1) 83 (78, 87) 0.0002
Any  strain (B variants as dissimilar) 46/2542 (1.8) 260/1764 (14.5) 87 (83, 91) 0.0056
Following  year 1 vaccination, all strains regardless of antigenic similarity
A/H1N1 14/1272 (1.1) 85/890 (9.6) 88 (80, 93) 0.0764
A/H3N2 32/2542 (1.3) 143/1746 (8.2) 84 (77, 89) 0.0003
B  47/2542 (1.8) 102/1746 (5.8) 68 (55, 77) <0.0001
Any  strain 94/2542 (3.7) 311/1746 (17.8) 79 (73, 83) <0.0001
Following  year 2 revaccination, antigenically similar strains
A/H1N1  2/1606 (0.1) 27/1173 (2.3) 94 (75, 99) 0.6610
A/H3N2 20/2354 (0.8) 137/1535 (8.9) 90 (84, 94) 0.1040
B  (original classiﬁcation) 12/2354 (0.5) 28/1535 (1.8) 70 (41, 85) 0.3280
B  (variants as dissimilar) 9/1583 (0.6) 23/1041 (2.2) 72 (39, 87) NE
Any  strain (original classiﬁcation) 33/2354 (1.4) 183/1535 (11.9) 87 (82, 91) 0.0222
Any  strain (B variants as dissimilar) 30/2354 (1.3) 179/1535 (11.7) 88 (83, 92) 0.0283
Following  Year 2 Revaccination, All Strains Regardless of Antigenic Similarity
A/H1N1 2/1606 (0.1) 27/1173 (2.3) 94 (75, 99) 0.6610
A/H3N2  35/2354 (1.5) 186/1535 (12.1) 88 (84, 92) 0.1514
B  55/2354 (2.3) 76/1535 (5.0) 43 (19, 59) 0.0107
Any  strain 91/2354 (3.9) 275/1535 (17.9) 78 (72, 82) <0.0001
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aused by A/H1N1, 55% (95% CI: 38, 67) fewer illnesses caused by
/H3N2, and 32% (95% CI: 14, 46) illnesses caused by B strains.
.3.  Efﬁcacy of LAIV by gender and region
When analyzed by gender, LAIV efﬁcacy versus placebo in year
 was higher among females. Efﬁcacy against antigenically similar
trains was 89% (95% CI: 84, 93) among females compared with 75%
95% CI: 66, 82) among males. However, efﬁcacy after revaccination
n year 2 was similar by gender, with efﬁcacy of 90% (95% CI: 82, 94)
mong females and 86% (95% CI: 77, 91) among males. Additionally,
AIV efﬁcacy relative to TIV was comparable in males (40% [95% CI:
4, 52] fewer cases for all strains regardless of antigenic match) and
emales (59% [95% CI: 45, 69] fewer cases). By region, LAIV efﬁcacy
stimates relative to placebo and TIV for children from Europe, the
nited States, and Middle East were robust and were similar to or
igher than those observed in the overall population. LAIV efﬁcacy
n year 1 relative to placebo against all strains was similar across
ll regions. LAIV efﬁcacy against similar strains relative to placebo
n year 1 for children from Asia (71% [95% CI: 59, 80]) was lower
han the efﬁcacy observed in the overall population. However, this
ifference was due to the disproportionate circulation of drifted B
iruses in Asia; LAIV efﬁcacy in children from Asia was 81% (95% CI:
7, 89) in year 1 against similar strains when drifted B viruses were
lassiﬁed as dissimilar. For placebo-controlled and TIV-controlled
tudies, most regions had data from only a single study. Few data
ere available regarding LAIV efﬁcacy in year 2 relative to placebo
n South America and Africa, and few to no data were available
egarding LAIV efﬁcacy relative to TIV in Asia, South America, and
frica.
. Discussion
This meta-analysis is the ﬁrst to provide a precise estimate
f the efﬁcacy of LAIV compared with placebo and TIV for chil-
ren and adolescents 2–17 years of age, the age group for whom
AIV is approved for use. LAIV exhibited consistently high efﬁcacy
ersus placebo and TIV against antigenically similar strains andall  strains regardless of antigenic match. Not surprisingly, efﬁcacy
relative to placebo was  lower when measured against all strains
regardless of match. This difference is largely attributable to the
recent cocirculation of 2 distinct lineages of inﬂuenza B strains,
only 1 of which is contained in the trivalent vaccine each year [23].
Because of antigenic differences between the 2 inﬂuenza B lineages,
efﬁcacy against opposite-lineage inﬂuenza B strains is reduced
for all inﬂuenza vaccines; efﬁcacy of LAIV in children against
opposite-lineage B strains has been estimated to be approximately
30% [24].
LAIV efﬁcacy relative to TIV was high when measured against
similar strains (44%–50% fewer cases of inﬂuenza illness among
LAIV recipients) and all strains regardless of antigenic match (48%
fewer cases). LAIV efﬁcacy was consistently higher than TIV in all
studies and across types/subtypes. The only exception was that
the available sample was  unable to demonstrate a statistically sig-
niﬁcant difference between LAIV and TIV for antigenically similar
A/H3N2 strains; this is in part due to the limited circulation of
antigenically similar A/H3N2 strains during the 3 TIV-controlled
studies. However, the efﬁcacy of LAIV relative to TIV against all
A/H3N2 strains was  high at 55% (95% CI: 38, 67), due to the
high efﬁcacy of LAIV and lower efﬁcacy of TIV against antigeni-
cally dissimilar A/H3N2 strains. Placebo-controlled studies have
also demonstrated that LAIV efﬁcacy against antigenically dissim-
ilar A/H3N2 strains can be high [9]. However, when the antigenic
difference between the vaccine and circulating A/H3N2 strains is
considerable, as occurred with emergence of the A/Fujian variant
in 2003, LAIV efﬁcacy may  be reduced [10,25].
LAIV efﬁcacy after revaccination in year 2 with a single dose
was consistently higher compared with the efﬁcacy of 2 doses in
year 1, which is likely due to continuing immunity from the ﬁrst
season vaccination [26]. The sustained duration of LAIV protection
in children has been described previously. In 1 study in Asia in
which inﬂuenza circulated through 13 months after vaccination,
LAIV efﬁcacy was  74% (95% CI: 40, 89) during late-season out-
breaks that occurred 5.5–13 months after vaccination, which was
similar to the 69% (95% CI: 53, 80) efﬁcacy observed for the season
overall [27].
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Table  3
Relative efﬁcacy of LAIV versus TIV.
Inﬂuenza strain Study LAIV n/N (%) TIV n/N (%) Relative vaccine efﬁcacy (95% CI) Heterogeneity (Q)
Antigenically similar strains
A/H1N1 Ashkenazi  (2006) 0/790  (0.0) 6/819  (0.7) 100  (NE, 100)
Fleming (2006) 0/1109  (0.0) 5/1102 (0.5) 100 (NE, 100)
Belshe (2007) 1/2083 (0.0) 21/2083 (1.0) 95 (65, 99)
Meta-analysis 1/3982 (0.0) 32/4004 (0.8) 97 (77, 100) NE
A/H3N2 Ashkenazi  (2006) 10/790 (1.3) 5/819 (0.6) −107 (−504, 29)
Fleming (2006) 12/1109 (1.1) 12/1102 (1.1) 1 (−120, 55)
Meta-analysis 22/1899 (1.2) 17/1921  (0.9) −31  (−145, 30) 0.2729
B  (original classiﬁcation) Ashkenazi  (2006) 9/790  (1.1) 29/819 (3.5) 68 (32, 85)
Fleming (2006) 34/1109  (3.1) 53/1102 (4.8) 36 (3, 58)
Belshe (2007) 29/2083 (1.4) 40/2083 (1.9) 27 (−16, 55)
Meta-analysis 72/3982 (1.8) 122/4004 (3.0) 41 (21, 56) 0.1586
B  (variants as dissimilar) Ashkenazi (2006) 9/790 (1.1) 29/819 (3.5) 68 (32, 85)
Fleming (2006) 34/1109  (3.1) 53/1102 (4.8) 36 (3, 58)
Belshe (2007) 1/2083  (0.0) 5/2083 (0.2) 80 (−71, 98)
Meta-analysis 44/3982 (1.1) 87/4004 (2.2) 49 (27, 64) 0.1704
Any  strain (original classiﬁcation) Ashkenazi (2006) 19/790 (2.4) 39/819 (4.8) 49 (13, 71)
Fleming (2006) 46/1109  (4.1) 70/1102  (6.4) 35 (6, 55)
Belshe (2007) 30/2083 (1.4) 61/2083 (2.9) 51 (24, 68)
Meta-analysis 95/3982 (2.4) 170/4004 (4.2) 44 (28, 56) 0.5563
Any  strain (B variants as dissimilar) Ashkenazi (2006) 19/790 (2.4) 39/819 (4.8) 49 (13, 71)
Fleming (2006) 46/1109  (4.1) 70/1102  (6.4) 35 (6, 55)
Belshe (2007) 2/2083 (0.1) 26/2083 (1.2) 92 (68, 98)
Meta-analysis 67/3982 (1.7) 135/4004 (3.4) 50 (33, 62) 0.0014
All  strains regardless of antigenic similarity
A/H1N1 Ashkenazi (2006) 0/790 (0.0) 7/819 (0.9) 100 (NE, 100)
Fleming (2006) 0/1109 (0.0) 6/1102 (0.5) 100 (NE, 100)
Belshe (2007) 1/2083  (0.0) 21/2083  (1.0) 95 (65, 99)
Meta-analysis 1/3982 (0.0) 34/4004 (0.8) 97 (78, 100) NE
A/H3N2 Ashkenazi  (2006) 15/790 (1.9) 9/819 (1.1) −73 (−293, 24)
Fleming (2006) 17/1109  (1.5) 13/1102 (1.2) −30 (−166, 37)
Belshe (2007) 24/2083 (1.2) 102/2083 (4.9) 76 (63, 85)
Meta-analysis 56/3982 (1.4) 124/4004 (3.1) 55 (38, 67) <0.0001
B Ashkenazi  (2006) 9/790 (1.1) 30/819 (3.7) 69 (35, 85)
Fleming (2006) 35/1109  (3.2) 55/1102  (5.0) 37 (4, 58)
Belshe (2007) 72/2083 (3.5) 86/2083 (4.1) 16 (−14, 38)
Meta-analysis 116/3982 (2.9) 171/4004 (4.3) 32 (14, 46) 0.0340
Any Ashkenazi  (2006) 23/790 (2.9) 46/819 (5.6) 48 (15, 68)
Fleming (2006) 50/1109 (4.5) 73/1102 (6.6) 32 (3, 52)
Belshe (2007) 94/2083 (4.5) 205/2083 (9.8) 54 (42, 64)
)
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mMeta-analysis 167/3982 (4.2
AIV, live attenuated inﬂuenza vaccine; NE, not estimable, TIV, trivalent inactivated
Analyses of LAIV efﬁcacy by various subject characteristics
emonstrated LAIV is highly efﬁcacious in male and female chil-
ren as well as across multiple geographic regions. The ﬁnding of
igher efﬁcacy in female subjects in year 1 of placebo-controlled
tudies is not readily explained; the lack of a difference in year 2
f placebo-controlled studies suggests that the difference could be
ue to chance alone and not a true biologic difference. Even if true,
he difference would have no clinical relevance given that LAIV pro-
ided greater efﬁcacy compared with TIV in both male and female
ubjects. The impact of subject age on LAIV efﬁcacy was not eval-
ated in the current analysis. Additionally, data for children and
dolescents 7 through 17 years of age is limited to one single-season
tudy that compared LAIV and TIV. However, a previous analysis of
AIV efﬁcacy by age in studies with broad enrollment age ranges
emonstrated that LAIV efﬁcacy does not decline with increasing
ge or repeated exposure to inﬂuenza in children up to 17 years of
ge [28].
In  addition to the incidence of culture-conﬁrmed inﬂuenza ill-ess, all of the studies in the current analysis that were conducted
n children 6 years of age and younger prospectively evaluated
he incidence of acute otitis media (AOM). Among children 24–71
onths of age, LAIV reduced the incidence of inﬂuenza-associated324/4004  (8.1) 48 (38, 57) 0.1898
enza vaccine.
AOM by 91% (95% CI: 84, 96) relative to placebo and 62% (95%
CI: 21, 83) relative to TIV. Additionally, LAIV reduced the severity
of inﬂuenza illness among breakthrough cases in children 24–71
months of age, as the rate of AOM among subjects with inﬂuenza
was 57% (95% CI: 19, 79) lower among LAIV recipients relative to
placebo recipients [29].
4.1.  Limitations
As  expected, signiﬁcant heterogeneity was  demonstrated in
some comparisons. This can be explained by slight variations in the
trials with regard to circulating strains during different inﬂuenza
seasons, previous exposure of participants to inﬂuenza vaccination
or disease, and other factors. However, the numerical values of the
efﬁcacy estimates across studies were similar. Certain subgroup
analyses, especially those examining regional differences, con-
sisted of only 1 study in each region and thus should be interpreted
with caution. The majority of study participants were younger than
7 years of age; only one single-season study presented data for chil-
dren and adolescents 7–17 years of age. However, LAIV efﬁcacy in
children and adolescents has not been shown to vary as a function
of age or pre-existing immunity to inﬂuenza [28].
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Consistent with the previous meta-analysis by Rhorer et al., the
resent analysis used a ﬁxed effects rather than a random effects
odel. A random effects model would be more appropriate if vac-
ine efﬁcacy was assumed to differ among trials. However, the
mall number of trials available could result in a substantial Type
 error rate [30]. Because the objective of the current analysis was
o provide a weighted average of vaccine efﬁcacy estimates across
ultiple studies, a ﬁxed effects model is more appropriate.
.  Conclusions
In children 2 through 17 years of age, LAIV has demonstrated
igh efﬁcacy after 2 doses in year 1 and after revaccination with a
ingle dose in year 2. Efﬁcacy was similar for A/H1N1, A/H3N2, and
 strains. LAIV demonstrated greater efﬁcacy compared with TIV in
ll 3 studies comparing the 2 vaccines. LAIV efﬁcacy estimates rela-
ive to placebo and TIV for children from Europe, the United States,
nd Middle East were robust and were similar to or higher than
hose observed in the overall population. This meta-analysis pro-
ides more precise estimates of LAIV efﬁcacy among the approved
ediatric age group and should provide reassurance regarding the
outine use of LAIV in eligible children 2 years of age and older.
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